Al‐Ola Abdallah

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · The Lancet Oncology · 2019 · 772 citations

Hematological Malignancy, Medicine, Pathology +6

Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros et al. · Cancer · 2021 · 140 citations · Full text

Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access

Nausheen Ahmed, Moazzam Shahzad, Ernie Shippey et al. · Transplantation and Cellular Therapy · 2022 · 130 citations · Full text

Health Care Disparity, Immunology, Health Disparities +23

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 127 citations

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Sagar Lonial, Rakesh Popat, Cyrille Hulin et al. · The Lancet Haematology · 2022 · 83 citations

Hematological Malignancy, Medicine, Hematology +8